Xilio Therapeutics Awards $7,400 in Stock Options to Strategic New Employees - Stock Titan
2 days ago • Google News
Xilio Development Inc (XLO)
US$ 0.8285-1.13%
Price Chart
Key Statistics
Market Cap
$ 36.14M
P/E Ratio
0.00
Revenue (TTM)
$ 9.27M
Volume
116.12K
52W High
$ 1.70
52W Low
$ 0.62
Dividend Yield
0.00%
Beta
0.02
Technicals
50-Day MA
0.7626
200-Day MA
0.8706
52 Week High
1.7
52 Week Low
0.62
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
Employees
64
Headquarters
Waltham, MA
CEO
Dr. Rene Russo BCPS, Pharm.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg